BIONTECH SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.17 USD | -0.27% |
|
-0.97% | -18.35% |
| Apr. 15 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |  |
| Apr. 15 | Market outlook is uncertain, but optimism prevails | |
| Sales 2024 * | 2.79B 2.97B | Sales 2025 * | 2.73B 2.91B | Capitalization | 19.53B 20.78B |
|---|---|---|---|---|---|
| Net income 2024 * | -420M -447M | Net income 2025 * | -503M -535M | EV / Sales 2024 * | 1.99 x |
| Net cash position 2024 * | 13.98B 14.88B | Net cash position 2025 * | 13.65B 14.52B | EV / Sales 2025 * | 2.15 x |
| P/E ratio 2024 * |
-41.7
x | P/E ratio 2025 * |
-43.7
x | Employees | 6,133 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioNTech SE
More recommendations
More press releases
More news
| 1 day | -0.27% | ||
| 1 week | -0.97% | ||
| Current month | -6.59% | ||
| 1 month | -7.33% | ||
| 3 months | -11.65% | ||
| 6 months | -8.70% | ||
| Current year | -18.35% |
1 week
85.40
88.96
1 month
85.2193.84
Current year
85.21114.70
1 year
85.21125.83
3 years
85.21464.00
5 years
12.53464.00
10 years
12.53464.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 08-06-01 |
Özlem Türeci
FOU | Founder | 57 | 08-06-01 |
Jens Holstein
DFI | Director of Finance/CFO | 60 | 21-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rudolf Staudigl
BRD | Director/Board Member | 69 | 21-12-31 |
| Director/Board Member | 67 | 08-06-01 | |
Helmut Jeggle
CHM | Chairman | 53 | 08-06-01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.92% | 1 M€ | 0.00% | - | |
| 2.63% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 86.17 | -0.27% | 567,937 |
| 24-04-17 | 86.4 | +0.07% | 1,264,673 |
| 24-04-16 | 86.34 | -1.76% | 782,142 |
| 24-04-15 | 87.89 | +1.63% | 753,281 |
| 24-04-12 | 86.48 | -0.61% | 726,723 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
2024-05-05
- Q1 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
81.21
EUR
Average target price
107
EUR
Spread / Average Target
+31.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.35% | 20.82B | |
| -3.30% | 102B | |
| +1.79% | 96.84B | |
| -0.44% | 21.48B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B | |
| -21.69% | 8.88B |
- Stock Market
- Equities
- BNTX Stock
